Signs of cardiac amyloidosis are present earlier than many clinicians realize, and early diagnosis and treatment should save lives. Read More ›

Cardiologists outline how to spot indicators of amyloidosis, what criteria to use to diagnose the disease, and how to distinguish between types of amyloidosis. Read More ›

Remission for cardiac light chain amyloidosis for >1 year may be associated with changes in myocardial composition without a reduction in extracellular volume. Read More ›

A new review outlines the applications and limitations of different options for the diagnosis of cardiac amyloidosis. Read More ›

A guide to understanding the characteristics, diagnosis, and management of transthyretin amyloidosis is now available for multidisciplinary team members. Read More ›

A new study reports high antibody response rates after COVID-19 vaccination among patients with monoclonal gammopathies of unknown significance, smoldering myeloma, multiple myeloma, or light chain amyloidosis. Read More ›

Cardiologists describe red flags that should raise suspicion of cardiac amyloidosis and provide a guide to noninvasive diagnostic techniques as alternatives to cardiac biopsy. Read More ›

As with the ventricles, amyloid infiltration in the atria may affect the severity of transthyretin amyloid cardiomyopathy. Read More ›

A study examined the hematologic and organ response rates to daratumumab in patients with relapsed/refractory light chain amyloidosis. Read More ›

Ixazomib plus dexamethasone may not improve response rate compared with physician’s choice of care but may delay organ deterioration and mortality in relapsed/refractory light chain amyloidosis. Read More ›

Page 1 of 3

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: